Available online on https://ijarms.com

International Journal of Advance Research in Medical Science 2025; 1(2):5-13

(Review Article)

Congestive Heart Failure: A Review

Jitendra Kumar Gupta[1], Abhishek Saini[2]

[1]Professor, Department of Pediatrics, Mahatma Gandhi University of Medical Sciences & Technology, Jaipur, Rajasthan, India

[2]Associate Professor , Department of Pediatrics, Mahatma Gandhi University of Medical Sciences & Technology, Jaipur , Rajasthan, India

Received: 01/06/2025/ Revised: 28/05/2025/ Accepted: 13-06-2025

Corresponding Author: Dr. Jitendra Kumar Gupta

Conflict of interest: Nil

Abstract

Background: Congestive heart failure (CHF) is a complex clinical pattern characterized by hamstrung myocardial performance, performing in compromised blood force to the body. CHF results from any complaint that impairs ventricular stuffing or ejection of blood to the systemic rotation. Cases generally present with fatigue and dyspnoea, reduced exercise forbearance, and systemic or pulmonary traffic. The etiology of HF is variable and expansive. A comprehensive assessment is needed when assessing a case with HF. The general operation aims at relieving systemic and pulmonary traffic and stabilization of hemodynamic status, anyhow of the cause. This exertion reviews the evaluation and operation of congestive heart failure and highlights the part of the healthcare platoon in perfecting care for cases with this condition.

Objectives: Apply the staging and classification systems of heart failure. Assess and cover cases with heart failure for signs of decompensation, fluid retention, and response to treatment. Select applicable individual tests, like echocardiography and biomarker assays, to prop in heart failure opinion and monitoring. Unite with multidisciplinary healthcare brigades, including cardiologists, nurses, and druggists, to insure coordinated and comprehensive care for heart failure cases. Access free multiple choice questions on this content.

Keywords: Heart Failure (HF), Congestive Heart Failure (CHF), Decompensation, Ejection Fraction, Pulmonary Congestion, Echocardiography, Biomarkers (e.g., BNP, NT-proBNP) ,Multidisciplinary Care, Ventricular Dysfunction, Fluid Retention.

INTRODUCTION

Congestive heart failure (CHF), as defined by the American College of Cardiology (ACC) and the American Heart Association (AHA), is" a complex clinical pattern that results from any structural or functional impairment of ventricular stuffing or ejection of blood. " Ischemic heart complaint is the leading cause of death worldwide and also the leading cause of CHF. CHF is a common complaint worldwide with a high morbidity and mortality rate. With an estimated frequency of 26 million people worldwide, CHF contributes to increased healthcare costs, reduces functional capacity, and significantly affects quality of life. It's imperative to diagnose and effectively treat the complaint to help intermittent hospitalizations, drop morbidity and mortality, and enhance patient issues. The etiology of heart failure (HF) is variable and expansive. The general operation aims at relieving systemic and pulmonary traffic and stabilization of hemodynamic status, anyhow of the cause. The treatment of HF requires a multifaceted approach involving patient education, optimal drug administration, and dwindling acute exacerbations.

Left ventricle ejection bit (LV EF) is used to classify HF.

HF with decreased ejection (HFrEF) LV EF ≤ 40 %

HF with mildly reduced ejection bit LV EF 41- 49 and substantiation of HF (elevated cardiac biomarkers or elevated stuffing pressures)

HF with saved ejection bit (HFpEF) LV EF ≥ 50 and substantiation of HF (elevated cardiac biomarkers or elevated stuffing pressures)

HF with bettered ejection bit LV EF> 40, with preliminarily proved LV EF ≤ 40%.

Cases with HFpEF have traditionally been underdiagnosed but comprise between 44 and 72 of CHF cases. On echocardiogram (echo), LV EF ≥ 50 with substantiation of disabled diastolic function. The most significant threat factor is hypertension (HTN), and other threat factors include aged age, womanish coitus, and diabetes. The ACC and the AHA together classify HF by stages, with the first 2 stages being asymptomatic and the alternate 2 being classified by inflexibility of symptoms.

ACC/ AHA Heart Failure Stages

Stage A at threat for HF. No signs, structural heart complaint, or substantiation of elevated cardiac biomarkers, but threat factors are present. Threat factors include hypertension, diabetes, metabolic

pattern, cardio toxic specifics, or having an inheritable variant for cardiomyopathy.

•Stage B Pre-HF. Cases have no signs or symptoms of HF but have structural heart complaint, substantiation of elevated stuffing pressures(by invasive or non-invasive assessment), or persistently elevated cardio markers in the absence of other reason for increased marker an example chronic disease kidney.

•Stage C Cases with structural heart complaint and current or once history of HF symptoms.

•Stage D Cases with refractory symptoms that intrude with diurnal life or intermittent hospitalization despite targeted guideline- directed medical remedy.

The New York Heart Association Functional Bracket is used for cases with symptoms of HF. This system is subjectively determined by clinicians and is extensively used in clinical practice to direct remedy.

Epidemiology

The global magnitude of the complaint cannot be directly assessed given the significant differences in geographical distribution, assessment styles, lack of imaging modalities, and non-adherence to the invariant staging and opinion of the complaint. Roughly1.2 million hospitalizations were due to CHF in 2017, with an increase in the chance of cases with HFpEF compared to HFrEF.

By some reports, the prevalence rate has metamorphosed; still, the frequency increases as further cases admit remedy. This has not restated to advanced quality of life or a drop in the number of hospitalizations for cases with CHF. According to the Global Health Data Exchange registry, the current worldwide frequency of CHF is64.34 million cases. This translates to9.91 million times lost due to disability (YLDs) and346.17 billion US bones in healthcare expenditure.

Age is a major determinant of HF. Anyhow of the cause or the description used to classify cases with HF, the frequency of HF increases acutely with age. The Framingham Heart Study showed CHF frequency to be 8 per 1000 males progressed 50 to 59 times, with an increase to 66 per 1000 males progressed 80 to 89. The prevalence of HF in men doubles with each 10- time age increase after the age of 65, whereas in women, for the same age cohort, the prevalence triplets. Men have advanced rates of heart complaint and CHF than women worldwide.

The global registry also notes a partiality for a race with a 25 advanced frequency of HF in Black cases than in White cases. HF is still the primary cause of hospitalization in the senior population and accounts for8.5 of cardiovascular-affiliated deaths in the United States.

International statistics regarding the epidemiology of HF are analogous. The prevalence increases dramatically with age, metabolic threat factors, and a sedentary life. Ischemic cardiomyopathy and hypertension are significant causes of HF in developing countries. A notable difference grounded on a review of small cohort studies from these nations is a advanced frequencies of insulated right HF. The theoretical cause of this is allowed to be due to the advanced frequencies of tuberculous, pericardial, and lung conditions. There's a lack of robust data to corroborate these claims.

Etiology

There are numerous etiologist of CHF, and coronary roadway complaint (CAD) causing ischemic heart complaint is the most common cause. Every attempt should be made to identify causative factors to help guide treatment strategies. The etiologist can be astronomically classified as natural heart complaint and pathologies that are infiltrative, natural, valvar, myocarditis- related, high- affair failure, and secondary to systemic complaint. These groups have significant imbrication. The 4 most common etiologist responsible for about two- thirds of CHF cases are ischemic heart complaint, habitual obstructive pulmonary complaint (COPD), hypertensive heart complaint, and rheumatic heart complaint. Advanced- income countries have advanced rates of ischemic heart complaint and COPD; lower- income countries have advanced rates of hypertensive heart complaint, cardiomyopathy, rheumatic heart complaint, and myocarditis.

Ischemic heart disease is by far the most common cause of CHF worldwide. Ischemia leads to a lack of blood inflow to heart muscles, reducing the EF. Prevalence is adding in developing countries as they borrow a more Western diet and life, and bettered medical care decreases the contagious burden in these countries(myocarditis is frequently infection-affiliated.)

Valvular heart disease is another common natural heart condition that can beget CHF. Rheumatic heart complaint is the most common cause of valvular heart complaint in children and youthful grown-ups worldwide. It's caused by an vulnerable response to group A Streptococcus and primarily causes mitral and aorticstenosis. The most common overall cause of valvular complaint is age- related degeneration, and the aortic stopcock is the most generally affected stopcock. Women are more likely to witness mitral stopcock rheumatic heart complaint or mitral stopcock prolapse, while men are more likely to suffer from aortic stopcock conditions similar as regurgitation or stenosis. Endocarditis is also more common in men.

Hypertension causes CHF indeed in the absence of CAD or ischemic heart complaint. High blood pressure causes mechanical stress by increased afterload and neurohormonal changes that increase ventricular mass. HTN is also explosively associated with other comorbidities for CHF development, and aggressively treating hypertension is shown to lower the prevalence of CHF.

Cardiomyopathy is a miscellaneous group of conditions characterized by enlarged ventricles with disabled function not related to secondary causes

similar as ischemic heart complaint, valvular heart complaint, hypertension, or natural heart complaint. The most common types of cardiomyopathies are hypertrophic, ballooned, restrictive, arrhythmogenic right ventricular, and left ventricular no compaction.(6) In addition to CHF, cardiomyopathy can present as arrhythmia or unforeseen cardiac death, farther compelling the identification of underpinning diseases. Numerous of these conditions have an inheritable base, and a detailed family history of unforeseen cardiac death, especially in first- degree cousins aged than 35 times, should be taken. There are over 50 linked genes contributing to the development of dilated cardiomyopathy alone. Inheritable determinants have variable phenotypic expression, and numerous monogenetic factors also affect the clinical symptoms. Some of these factors include diabetes, poisonous exposure, or gestation. Fabray complaint is a rare glycogen storehouse complaint that can beget CHF symptoms through a hypertrophic cardiomyopathy pattern.

Obesity is a leading cause of CHF in cases youngish than 40 times, according to the" Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity"(the CHARM study). The" rotundity incongruity" described away has significant study excrescencies and is deduced from aged data. It's allowed that over to 10 of CHF cases are attributable to rotundity alone. Cases with rotundity are more likely to have HFpEF, conceivably secondary to adipose- produced cytokines similar as IL- 1b, IL- 8, and TNFα. Adipose towel also degrades natriuretic peptides. Tachycardia and arrhythmia can induce a low- affair CHF state. There's generally dilation of all cardiac chambers, and there's preservation or thinning of biventricular wall consistence. Electrophysiological changes, including prologue duration and dropped breadth of action capabilities in the myocytes, accompany this. All of these factors induce the typical neurohormonal response causing CHF. With rate control, these changes are frequently reversible due to myocardial hibernation. This may be incompletely due to activation of the renin- angiotensin- aldosterone axis, causing sodium and water retention, as well as upregulation of erythropoietin- stimulating agent, both of which will beget increased blood volume. Sustained tachycardia with or without atrial fibrillation can also beget CHF. High- affair cardiac failure can be associated with thiamine insufficiency, which is a rare condition set up primarily among cases who are senior, homeless, or have alcohol abuse complaint. Thiamine insufficiency causes dropped ATP product with an accumulation of adenosine, which causes systemic vasodilation. This leads to lowered systemic vascular resistance and increased cardiac affair. This evolves to weakened myocardium and dropped EF. Diuretic use can also beget urinary thiamine loss, farther compounding the situation. Other common causes of high- affair cardiac failure are rotundity, liver complaint, and arteriovenous shunts. The causative physiologic changes are dropped afterload (ie, systemic vascular resistance) and increased metabolism. These can frequently present with saved EF, pulmonary traffic, increased filling pressures, and elevated natriuretic peptides. * Pathophysiology *

It is a progressive complaint. Any acute personality to cardiac structure or acute revision secondary to inheritable mutation, cardiac towel infiltration, ischemia, valvular heart complaint, myocarditis, or acute myocardial injury may initiate the compensatory medium, which, once exhausted, results in maladaptation. In the original stages of CHF, several compensatory mechanisms essay to maintain cardiac affair and meet the systemic demands. The habitual activation of the sympathetic nervous system results in reduced beta- receptor responsiveness and adrenaline stores.

This results in changes in myocyte juvenescence, myocardial hypertrophy, and myocardial hyper contractility. The increased sympathetic drive also results in the activation of the renin- angiotensin- aldosterone system (RAAS) system, systemic vasoconstriction, and sodium retention. A drop in cardiac affair and increased sympathetic drive stimulate the RAAS, leading to increased swab and water retention, along with increased vasoconstriction. This farther energies the maladaptive mechanisms in the heart and causes progressive HF. In addition, the RAAS system releases angiotensin II, which has been shown to increase myocardial cellular hypertrophy and interstitial fibrosis, contributing to myocardial redoing. A drop in cardiac affair stimulates the neuroendocrine system with a release of epinephrine, norepinephrine, endothelin- 1(ET- 1), and vasopressin. These intercessors beget vasoconstriction, leading to increased afterload. There's an increase in cyclic adenosine monophosphate (cAMP), which causes an increase in cytosolic calcium in the myocytes. This increases myocardial contractility and further prevents myocardial relaxation. Increased afterload and myocardial contractility with disabled myocardial relaxation increase myocardial oxygen demand. This paradoxical need for increased cardiac affair to meet myocardial demand ultimately leads to myocardial cell death and apoptosis. As apoptosis continues, a drop in cardiac affair with increased demand leads to an immortalizing cycle of increased neurohumoral stimulation and maladaptive hemodynamic and myocardial responses. The loss of myocytes decreases EF (cardiac contractility), which leads to deficient LV evacuating. Increased LV volume and pressure beget pulmonary traffic. Renal hypoperfusion causes the release of antidiuretic hormone (ADH), farther potentiating sodium and water retention. Increased central venous and intraabdominal pressure causes reduced renal blood inflow, further dwindling GFR.



Figure 1: Heart condition in cardiac heart failure

Decompensated CHF is characterized by supplemental vasoconstriction and increased preload delivery to the overburdened heart. The natriuretic peptides BNP and ANP are buried but are ineffective in neutralizing the redundant sodium and water retention. Neprilysin is an enzyme that breaks down several hormones, including BNP, ANP, and bradykinin; it targets several new rectifiers. It's always used with an angiotensin receptor blocker because it increases angiotensin II situations, and when administered with an ACE asset, it causes significant angioedema. Causes of CHF are resolve about inversely between HFrEF and HFpEF but bear different treatment plans. In HFpEF, there's a drop in myocardial relaxation and an increase in the stiffness of the ventricle due to an increase in ventricular afterload. This perpetuates a analogous maladaptive hemodynamic compensation and leads to progressive HF. Cases with HFpEF tend to be aged, womanish, and hypertensive. Atrial fibrillation and anemia are also more likelycolikely co-occurring conditions. There's some substantiation that the prognostic is worse than those with HFrEF. It's possible that applicable targets haven't been linked for optimal remedial interventions.

History

The opinion and bracket of HF are primarily grounded on the presence and inflexibility of symptoms and physical test findings. It's imperative to gain a detailed history of symptoms, underpinning medical conditions, and functional capacity to treat the case adequately. Acute CHF presents primarily with signs of traffic and may also present with organ hypoperfusion or cardiogenicshock.The most generally reported symptom is briefness of breath. This must be further classified as exertional, positional (orthopnea), and whether acute or habitual. Other generally reported symptoms of CHF include casket pain, anorexia, and exertional fatigue. Anorexia is due to hepatic traffic, bowel edema, and reduced blood inflow to splanchnic rotation. Some cases may present with a prostrate cough due to orthopnea. Cases may also witness abdominal discomfort due to hepatic traffic or ascites.

Cases with arrhythmias can present with pulsations, presyncope, or blackout. Another symptom that increases morbidity is edema, especially of the lower extremities. This can limit mobility and balance; total body water and weight increases of> 20 lbs aren't uncommon. While cases with acute HF present with overt respiratory torture, orthopnea, and ferocious nightly dyspnea, cases with habitual heart failure tend to dock their physical exertion; hence, symptoms may be obscured. It's essential to identify triggers of acute decompensation similar as recent infection, resistance with cardiac specifics, use of NSAIDs, or increased swab input

Physical examination

Examination findings vary with the stage and perceptivity of the complaint. Cases may have insulated symptoms of left- sided HF, right- sided HF, or combined. General physical examination the general appearance of cases with severe CHF or those with acutely decompensated HF includes anxiety, diaphoresis, tachycardia, and tachypnea. Cases with habitual decompensated HF can appear cachexic. On casket examination, the classical finding of pulmonary rales translates to heart failure of moderate- to-severe intensity. Gasping may be present in acute decompensated heart failure.

As the inflexibility of pulmonary traffic increases, frothy and blood- pigmented foam may be seen. It's important to note that the absence of rales doesn't count pulmonary traffic. Jugular venous distention is another classical finding that must be assessed in all cases with HF. In cases with elevated left- sided stuffing pressures, hepatojugular influx (sustained increase in JVP of> 4 cm after applying pressure over the liver with the case lying at a 45 ° angle) is frequently seen. Cases with Stage D HF may show signs of poor perfusion, similar as hypotension, reduced capillary cache, cold extremities, poor mentation, and reduced urine affair.

There may be pulsus alternant (an interspersing weak and strong palpitation), suggestive of severe ventricular dysfunction. The palpitation can be

irregular in the presence of atrial fibrillation or ectopic beats. Some degree of supplemental edema is present with utmost HF. Weight gain is another system for assessing volume retention, and precise daily weights can be a useful monitoring tool. Precordial findings in cases with HF include an S3 gallop, or displaced apex beat (dilated heart). There may be murmurs of associated valvular lesions similar as the pansystolic murmur of mitral regurgitation or tricuspid regurgitation, systolic ejection murmur of aortic stenosis, or early diastolic murmur of aortic regurgitation. Cases with pulmonary hypertension may have palpable or loud P2 or parasternal heave. Cases with natural heart complaint may also have associated clubbing, cyanosis, and splitting of the alternate heart sound. An S3 gallop is the most significant and early finding associated with HF. Cases with hypertensive heart complaint may have an S4 or loud A2. Cases with HF with saved EF may have an S4 gallop related to ventricular resistance. The generally used Framingham Diagnostic Criteria for Heart Failure bear the presence of 2 major criteria or 1 major and 2 minor criteria to make the opinion. This clinical individual tool is largely sensitive for the opinion of HF but has a fairly low particularity. The Framingham Diagnostic criteria are as follows Major Criteria Acute pulmonary edema Cardiomegaly Hepatojugular kickback Neck tone distention ferocious nightly dyspnea or orthopnea Pulmonary rales Third heart sound(S3 Gallop) Minor Criteria Ankle edema Dyspnea on exertion Hepatomegaly nightly cough Pleural effusion Tachycardia(heart rate lesser than 120 beats per nanosecond)

There may be pulsus alternans (an interspersing weak and strong palpitation), suggestive of severe ventricular dysfunction. The palpitation can be irregular in the presence of atrial fibrillation or ectopic beats. Some degree of supplemental edema is present with utmost HF. Weight gain is another system for assessing volume retention, and precise daily weights can be a useful monitoring tool. Precordial findings in cases with HF include an S3 gallop, or displaced apex beat (dilated heart). There may be murmurs of associated valvular lesions similar as the pansystolic murmur of mitral regurgitation or tricuspid regurgitation, systolic ejection murmur of aortic stenosis, or early diastolic murmur of aortic regurgitation.

Cases with pulmonary hypertension may have palpable or loud P2 or parasternal heave. Cases with natural heart complaint may also have associated clubbing, cyanosis, and splitting of the alternate heart sound. An S3 gallop is the most significant and early finding associated with HF. Cases with hypertensive heart complaint may have an S4 or loud A2. Cases with HF with saved EF may have an S4 gallop related to ventricular resistance. The generally used Framingham Diagnostic Criteria for Heart Failure bear the presence of 2 major criteria or 1 major and 2 minor criteria to make the opinion. This clinical individual tool is largely sensitive for the opinion of HF but has a fairly low particularity.

Evaluation

Comprehensive assessment is needed when assessing a case with HF. This includes a complete blood picture, iron profile, renal profile, and liver profile. After the introductory metabolic and blood panel, cases bear farther examinations, depending on the etiology and clinical stage. A CBC may suggest anemia or leukocytosis suggestive of an infection driving CHF.

A complete renal profile is necessary for all cases with HF. It indicates the degree of renal injury associated with HF and attendants drug choice. It's essential to know birth renal function before the case is started on specifics, including renin- angiotensin-aldosterone(RAAS) impediments, sodium- glucose transporter- 2(SGLT- 2) impediments, or diuretics. Serum sodium position has prognostic value as a predictor of mortality in cases with habitual HF." The issues of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure"(OPTIME- CHF) trial demonstrated a significantly increased threat of in- sanitarium mortality as well as 30- day mortality in cases with HF who presented with hyponatremia.

A liver profile is generally performed. Hepatic traffic secondary to HF may affect in elevated gamma-glutamyl transferase situations, aspartate aminotransferase (AST), and alanine aminotransferase (ALT).

Urine studies can be useful indiagnosis.However, urine and serum electrophoresis and monoclonal light chain assays should be performed, If amyloidosis issuspected.However, bone scintigraphy can be performed, If clinical dubitation is high despite negative testing for light chains. Urine studies can be useful indiagnosis.However, urine and serum electrophoresis and monoclonal light chain assays should be performed, If amyloidosis issuspected.However, bone scintigraphy can be performed, If clinical dubitation is high despite negative testing for light chains. Serum B- type natriuretic peptide(BNP) or N-terminalpro-BNP(NT- ProBNP) situations can prop in secerning cardiac from noncardiac causes of dyspnea in cases with nebulous donations. BNP is an independent predictor of increased left ventricular end- diastolic pressure, and it's used for assessing mortality threat in cases with HF. BNP situations relate with NYHA bracket, and the mileage is primarily used as a marker to assess treatment efficacity. NT- ProBNP is the chemically inert N-terminal scrap of BNP and has a longer partial- life. The rate of NT- ProBNP/ BNP varies depending on underpinning comorbidities and may be a useful tool in the future. (41) In cases with a clear clinical donation of HF, natriuretic peptides shouldn't be used to drive treatment plans. It's important to flash back that BNP and NT- ProBNP

Situations can be elevated in cases with renal dysfunction, atrial fibrillation, and elderly patients. Conversely, BNP levels can be falsely low in cases with obesity, hypothyroidism, and advanced heart failure due to myocardial fibrosis. Persistently elevated Troponin I or T suggests ongoing myocardial injury and predicts adverse outcomes and mortality. An electrocardiogram (ECG) may show evidence of previous infarction, chamber enlargement, intraventricular conduction delay, or arrhythmias, and may also offer clues to specific etiologies. A low-voltage and pseudo-infarction pattern is seen in cardiac amyloidosis, while an epsilon wave is indicative of arrhythmogenic right ventricular cardiomyopathy (ARVC). The presence of ventricular desynchrony, identified by a QRS duration greater than 120 ms, helps predict response to device therapy in heart failure (HF). Chest radiographs are commonly used to assess the degree of pulmonary congestion and cardiac silhouette for signs of cardiomegaly. Findings suggestive of congestive heart failure (CHF) include an enlarged cardiac silhouette, basal pulmonary edema, and vascular congestion. Kerley B lines may also be visible in florid HF. However, the absence of these findings does not rule out CHF in patients with a suggestive clinical presentation. Echocardiography is the first-line imaging modality in suspected HF due to its accessibility and bedside utility. It quantifies right and left ventricular function, reveals structural abnormalities in cardiac chambers and valves, and visualizes focal wall motion abnormalities. In patients with severe obesity, pregnancy, or those on mechanical ventilation, obtaining adequate acoustic windows may be challenging. Transesophageal echocardiography (TEE) serves as an alternative in such cases, though achieving adequate rate control in patients with tachyarrhythmias is necessary for image quality. Cardiac catheterization is often required for diagnosing ischemic cardiomyopathy and allows direct measurement of intracardiac pressures such as left ventricular end-diastolic pressure and pulmonary artery pressures. Computed tomography (CT) can be used to evaluate coronary artery disease in younger patients with ventricular dysfunction, though older patients often present with vascular calcifications. CT is also useful in congenital heart diseases causing HF and for detecting tumors or assessing stent patency and graft integrity. SPECT-Myocardial Perfusion Imaging is valuable in identifying ischemia in newly diagnosed left ventricular dysfunction cases not undergoing coronary angiography, particularly in patients with no history of ischemia but elevated troponin levels. ECG-gated SPECT imaging allows assessment of left ventricular ejection fraction (LVEF), regional wall motion, and wall thickening, although accuracy may be affected by irregular heart rhythms, low radiotracer count density, or extracardiac uptake. Gated imaging is also essential in distinguishing artifacts such as breast tissue or diaphragmatic attenuation. Cardiac magnetic resonance imaging (MRI) has become a critical tool in cases where a discrepancy exists between clinical presentation and echocardiographic findings. MRI offers detailed volumetric analysis, chamber size measurement, and functional evaluation of ventricles. It is especially useful in staging valvular heart diseases and in assessing complex congenital heart conditions. Furthermore, cardiac MRI is a noninvasive modality for evaluating conditions such as myocarditis, dilated cardiomyopathy, infiltrative cardiomyopathies like amyloidosis, and ARVC. Radionuclide multiple-gated acquisition (MUGA) scans provide accurate LVEF assessment and are helpful when discrepancies exist between other imaging modalities. Noninvasive stress imaging—including stress echocardiography, stress MRI, and SPECT—helps evaluate the benefit of coronary revascularization in ischemic cardiomyopathy. Genetic testing is indicated to identify hereditary mutations associated with cardiomyopathies, such as those involving Titin, lamin A/C, myosin heavy chain, and cardiac troponin T. The goal of managing chronic CHF is to improve symptoms, enhance quality of life, reduce hospitalizations, and lower cardiac mortality. Pharmacologic therapy focuses on symptom control and the initiation and titration of medications that reduce morbidity and mortality. Management strategies for different stages of HF are outlined by the American College of Cardiology and the American Heart Association. In Stage A patients (at risk for HF), guideline-directed medical therapy (GDMT) for hypertension and the use of SGLT-2 inhibitors in type 2 diabetes are recommended to prevent HF-related hospitalizations. Lifestyle modifications such as healthy diet, regular physical activity, weight maintenance, and smoking cessation are essential. Prognostic scoring systems like the Framingham Heart Failure Risk Score (1999), Health ABC Heart Failure Score (2008), ARIC Risk Score (2012), and PCP-HF Score (2019) are useful for estimating the risk of future HF events.

Treatment/ Management

The thing of remedy for habitual CHF is to ameliorate symptoms and quality of life, drop hospitalizations, and ameliorate cardiac mortality. The thing of pharmacologic remedy is to control symptoms and to initiate and escalate medicines that reduce mortality and morbidity in HF. operation for the separate stages of HF is outlined by the American College of Cardiology and the American Heart Association.

For Stage A (At- threat for HF)

In cases with hypertension, guideline- directed medical remedy (GDMT) should be used for the operation of hypertension.

In cases with type 2 diabetes, SGLT- 2 impediments are indicated to reduce HF hospitalizations. Life variations similar as healthy eating, physical exertion, maintaining a normal weight, and avoidance of smoking are indicated. The use of prognostication

scores is recommended in cases with HF to estimate the threat of unborn HF events.(45) exemplifications include the Framingham Heart Failure threat Score(1999), Health ABC Heart Failure Score(2008), ARIC Risk Score(2012), and PCP- HF score(2019).

There should be optimal operation of cardiovascular conditions in cases known to have coronary roadway complaint. Cases at threat for HF due to exposure to cardiotoxic specifics (eg, chemotherapy) should be managed with a multidisciplinary approach. Natriuretic peptide webbing and periodic evaluation are recommended.

For Stage B (Pre-HF)

Operation of Stage B is concentrated on precluding clinical HF and reducing mortality and adverse cardiovascular events. For cases with LV EF ≤ 40, ACEi should be used to help clinical HF and for mortality reduction. For cases with LV EF ≤ 40 and substantiation of previous or recent acute coronary pattern or myocardial infarction, the use of a statin and beta- blocker is recommended for reduction of mortality, CHF, and reducing adverse cardiovascular events. For cases with LV EF ≤ 30 and entering optimal medical remedy, with NYHA- class I and an anticipation of meaningful survival of further than 1 time, a primary forestalment ICD is recommended.

Beta- blockers are recommended for cases with LV EF ≤ 40, irrespective of the etiology, to help characteristic HF. For cases with LV EF ≤ 50, the use of thiazolidinediones andnon-dihydropyridine calcium channel blockers increases the threat of adverse issues and HF hospitalizations, so should be avoided. Stopcock form, relief, or interventions have associated guidelines for asymptomatic valvular heart complaint. Cases with natural heart complaint also have associated guidelines. For Stage (CHF)

For Stage (CHF) Multidisciplinary operation is indicated for perfecting tone- care and mortality of cases with HF. Case education and social support are needed for optimal operation. Vaccination against respiratory ails is effective in reducing mortality. It's reasonable to screen cases for frailty, depression, low knowledge, low social support, and resource and transport logistics during healthcare hassles. A low-sodium diet is recommended.

Exercise training is effective in perfecting functional class and quality of life. For cases with traffic, diuretics ameliorate symptoms and reduce HF progression. A thiazide diuretic (similar as metolazone) should be added only to cases who don't respond well to a moderate or high cure of circle diuretics.

For cases with HFrEF, an ARNi is recommended to reduce mortality and morbidity. ARNi shouldn't be given to cases who are intolerant of ACEi, and an ARB should be substituted. For cases not suitable to take an ARNi due to profitable factors, the use of an ACEi or ARB is indicated.

ARNi shouldn't be used within 36 hours of the last cure of ACEi. For cases permitting ACEi/ ARB well, switching to ARNi is recommended, with a high profitable value. As with ACEi, ARNi shouldn't be given to cases with a history of angioedema.

For cases with HFrEF, the use of the beta- blockers carvedilol, bisoprolol, or sustained- release metoprolol is effective in reducing mortality and hospitalization. For cases with HFrEF, NYHA class II- IV, an eGFR of further than 30 mL/ min/1.73 m2 and a serum potassium of lower than5.0 mEq/ L, the use of MRA is recommended.

For cases with a serum potassium of further than5.0 mEq/ L, the use of MRA is dangerous. For cases with HFrEF, the use of SGLT- 2 impediments is recommended to reduce mortality and HF hospitalization, irrespective of the diabetes status. For African American cases with HFrEF and NYHA class III- IV, who are formerly entering optimal medical remedy (OMT), the addition of a combination of hydralazine and nitrate is recommended to reduce morbidity and mortality. This is of high profitable value.

For cases with HFrEF and intolerant to RAASi or in whom RAASi is contraindicated due to renal insufficiency, the use of a combination of hydralazine and nitrate might be effective. It's recommended to titrate specifics aggressively to achieve asked issues. This can be done as constantly as 1- 2 weeks as permitted.

Ivabradine can be useful in cases on OMT with and heart rate of further than 70 bpm, furnishing mortality benefits, and reducing HF hospitalization. Digoxin may be considered in characteristic cases with sinus meter despite acceptable thing- directed remedy to reduce the each- beget rate of hospitalizations, but its part is limited.

In cases with HFrEF and recent HF, an oral answerable guanylate cyclase stimulator (Vericiguat) might be useful in reducing mortality and HF hospitalization. Vericiguat is a answerable guanylate cyclase stimulator that stimulates the intracellular receptor for endogenous NO, which is a potent vasodilator. It also improves cardiac contractility.

Device remedy An implantable cardioverter-defibrillator(ICD) is indicated for primary forestallment of unforeseen cardiac death in cases with HF who have an LVEF of lower than or equal to 35 and an NYHA functional class of II to III while on thing- directed medical remedy. It's also indicated if a case has NYHA functional class I and an EF of lower than or equal to 30% on acceptable medical remedy.

Cardiac resynchronization remedy(CRT) with biventricular pacing is recommended in cases with HFrEF and an NYHA functional class of II to III or itinerant class IV with an LVEF lower than or equal to 35, QRS duration ≥ 150 msec, and sinus meter with left pack branch block(LBBB) morphology. It can also be considered innon-LBBB morphology and QRS ≥ 150 msec. Revascularization is indicated in named cases with coronary roadway complaint and HFrEF while on GDMT.

Prognosis

According to the Centers for Disease Control and Prevention (CDC), in December 2015, the rate of HF-related deaths dropped from103.1 deaths per 100,000 population in 2000 to89.5 in 2009 but latterly increased to96.9 in 2014. The report noted that the trend correlates with a shift from coronary heart complaint as the underpinning cause of HF deaths to metabolic conditions and other noncardiac causes of HF, similar as rotundity, diabetes, malice, habitual pulmonary conditions, and renal complaint. The mortality rate following hospitalization for HF is estimated at around 10 at 30 days, 22 at 1 time, and 42 at 5 times. This can increase to lesser than 50 for cases with stage D HF.

The Ottawa Heart Failure threat Score is a useful tool for determining prognostic in cases presenting to the exigency department with HF. This score is used to determine the 14- day mortality threat, sanitarium readmission, and acute coronary pattern to help arrive at safe disposition planning. Cases with a score of 0 are considered low threat. A score of 1 to 2 is considered moderate threat, a score of 3- 4 is considered high threat, and a score of 5 or advanced is considered veritably high threat. The scoring criteria are as follows

One point for each of the following

History of stroke or flash ischemic attack

Oxygen achromatism lower than 90%

Heart rate lesser than 110 bpm on the 3- nanosecond walk test

Acute ischemic ECG changes An NT- ProBNP position of lesser than 5000 ng/ L

Two points for each of the following previous history of mechanical ventilation for respiratory torture

Heart rate lesser than 110 bpm on presentation donation

Consultations

The consultation type onset on the disease stage and the management strategy. Mostly consulted specific involve HF specific, the cardiac transplant group for level D CHF, cardiac imaging radiologist, rehabilitations, dieticians.

REFERENCES

1. Matta AG, Carrié D. Epidemiology, Pathophysiology, Diagnosis, and Principles of Management of Takotsubo Cardiomyopathy: A Review. Med Sci Monit. 2023 Mar 06; 29:e939020.
2. Bairashevskaia AV, Belogubova SY, Kondratiuk MR, Rudnova DS, Sologova SS, Tereshkina OI, Avakyan EI. Update of Takotsubo cardiomyopathy: Present experience and outlook for the future. Int J Cardiol Heart Vasc. 2022 Apr; 39:100990.
3. Ahmad SA, Brito D, Khalid N, Ibrahim MA. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): May 22, 2023. Takotsubo Cardiomyopathy.
4. DeFilippis EM, Beale A, Martyn T, Agarwal A, Elkayam U, Lam CSP, Hsich E. Heart Failure Subtypes and Cardiomyopathies in Women. Circ Res. 2022 Feb 18; 130(4):436-454.
5. Wong CM, Hawkins NM, Jhund PS, MacDonald MR, Solomon SD, Granger CB, Yusuf S, Pfeffer MA, Swedberg K, Petrie MC, McMurray JJ. Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity). J Am Coll Cardiol. 2013 Nov 12; 62(20):1845-54.
6. Sciomer S, Moscucci F, Salvioni E, Marchese G, Bussotti M, Corrà U, Piepoli MF. Role of gender, age and BMI in prognosis of heart failure. Eur J Prev Cardiol. 2020 Dec; 27(2_suppl):46-51.
7. Volpe M, Gallo G. Obesity and cardiovascular disease: An executive document on pathophysiological and clinical links promoted by the Italian Society of Cardiovascular Prevention (SIPREC). Front Cardiovasc Med. 2023; 10:1136340.
8. Kim DY, Kim SH, Ryu KH. Tachycardia induced Cardiomyopathy. Korean Circ J. 2019 Sep; 49(9):808-817.
9. Anakwue RC, Onwubere BJ, Anisiuba BC, Ikeh VO, Mbah A, Ike SO. Congestive heart failure in subjects with thyrotoxicosis in a black community. Vasc Health Risk Manag. 2010 Aug 09; 6:473-7.
10. Schoenenberger AW, Schoenenberger- Berzins R, der Maur CA, Suter PM, Vergopoulos A, Erne P. Thiamine supplementation in symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled, cross-over pilot study. Clin Res Cardiol. 2012 Mar; 101(3):159-64.
11. DiNicolantonio JJ, Liu J, O'Keefe JH. Thiamine and Cardiovascular Disease: A Literature Review. Prog Cardiovasc Dis. 2018 May-Jun; 61(1):27-32.
12. Reddy YNV, Melenovsky V, Redfield MM, Nishimura RA, Borlaug BA. High-Output Heart Failure: A 15-Year Experience. J Am Coll Cardiol. 2016 Aug 02; 68(5):473-482.
13. Chayanupatkul M, Liangpunsakul S. Cirrhotic cardiomyopathy: review of pathophysiology and treatment. Hepatol Int. 2014 Jul; 8(3):308-15.
14. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder

15. EB, Shah SH, Shay CM, Spartano NL, Stokes A, Tirschwell DL, VanWagner LB, Tsao CW., American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2020 Update: A Report from the American Heart Association. Circulation. 2020 Mar 03; 141(9):e139-e596.
16. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 1993 Oct; 22(4 Suppl A):6A-13A.
17. Benjamin EJ, et al American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 Update: A Report from the American Heart Association. Circulation. 2017 Mar 07; 135(10):e146-e603.
18. Yusuf S, Joseph P, Rangarajan S, Islam S, Mente A, Hystad P, Brauer M, Kutty VR, Gupta R, Wielgosz A, AlHabib KF, Dans A, Lopez-Jaramillo P, Avezum A, Lanas F, Oguz A, Kruger IM, Diaz R, Yusoff K, Mony P, Chifamba J, Yeates K, Kelishadi R, Yusufali A, Khatib R, Rahman O, Zatonska K, Iqbal R, Wei L, Bo H, Rosengren A, Kaur M, Mohan V, Lear SA, Teo KK, Leong D, O'Donnell M, McKee M, Dagenais G. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet. 2020 Mar 07; 395(10226):795-808.
19. Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA. Controversies in ventricular remodelling. Lancet. 2006 Jan 28; 367(9507):356-67.
20. Kemp CD, Conte JV. The pathophysiology of heart failure. Cardiovasc Pathol. 2012 Sep-Oct; 21(5):365-71.
21. Ait Mou Y, Bollensdorff C, Cazorla O, Magdi Y, de Tombe PP. Exploring cardiac biophysical properties. Glob Cardiol Sci Pract. 2015; 2015:10.
22. Abassi Z, Khoury EE, Karram T, Aronson D. Edema formation in congestive heart failure and the underlying mechanisms. Front Cardiovasc Med. 2022; 9:933215.
23. Prausmüller S, Arfsten H, Spinka G, Freitag C, Bartko PE, Goliasch G, Strunk G, Pavo N, Hülsmann M. Plasma Neprilysin Displays No Relevant Association With Neurohumoral Activation in Chronic HFrEF. J Am Heart Assoc. 2020 Jun 02; 9(11):e015071.
24. Docherty KF, Vaduganathan M, Solomon SD, McMurray JJV. Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF. JACC Heart Fail. 2020 Oct; 8 (10):800-810.
25. Obokata M, Reddy YNV, Borlaug BA. Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction: Understanding Mechanisms by Using Noninvasive Methods. JACC Cardiovasc Imaging. 2020 Jan; 13 (1 Pt 2):245-257.
26. Kao DP, Lewsey JD, Anand IS, Massie BM, Zile MR, Carson PE, McKelvie RS, Komajda M, McMurray JJ, Lindenfeld J. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. Eur J Heart Fail. 2015 Sep;17(9):925-35